Sheila Krishnan Mody1, Jessica R Gorman2, Lisa P Oakley2, Tracy Layton3, Barbara A Parker3,4, Danielle Panelli5. 1. Division of Family Planning, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, 9300 Campus Point Dr, MC 7433, La Jolla, San Diego, CA, 92037, USA. smody@ucsd.edu. 2. College of Public Health and Human Sciences, Oregon State University, Corvallis, OR, USA. 3. Moores Cancer Center, University of California, San Diego, OR, USA. 4. Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, OR, USA. 5. Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Stanford University, Stanford, CA, USA.
Abstract
PURPOSE: To explore contraceptive counseling and utilization among breast cancer survivors. METHODS: We enrolled reproductive-aged women with a history of breast cancer for a cross-sectional study. Participants were recruited via the Athena Breast Health Network and via the Young Survival Coalition's social media postings. Descriptive statistics were calculated to understand utilization of and feelings about contraceptive methods before, during, and after breast cancer treatment. RESULTS: Data presented here are from an online survey of 150 breast cancer survivors who completed the survey. Seventy-one percent (n = 105) of respondents reported being sexually active and not pregnant during their primary cancer treatment (surgery, chemotherapy, and/or radiation). Of these, 90% (n = 94) reported using any form of contraceptive, and the most common method was condoms (n = 55, 52%). Respondents reported that safety concerns had the biggest influence on their contraception method choice. Sixty-one percent (n = 92) reported receiving contraceptive counseling by their oncologist either before or after treatment; however, 49% (n = 45) of those did not receive a specific recommendation for a contraceptive method. Of respondents who reported receiving contraceptive counseling from their gynecologist, 44% (n = 35) reported that their gynecologist specifically recommended a copper intrauterine device (IUD). The majority of respondents (n = 76, 52%) wanted their oncologist to discuss contraceptive options with them and preferred to receive this counseling at the time of diagnosis (n = 81, 57%). CONCLUSIONS: Breast cancer survivors in this study remained sexually active across the cancer care continuum and predominantly used condoms as their contraceptive method during treatment. Breast cancer patients would prefer contraceptive counseling from their oncologist at the time of their cancer diagnosis. IMPLICATION FOR CANCER SURVIVORS: Education efforts in the future should focus on initiatives to improve comprehensive contraceptive counseling at the time of diagnosis by an oncologist.
PURPOSE: To explore contraceptive counseling and utilization among breast cancer survivors. METHODS: We enrolled reproductive-aged women with a history of breast cancer for a cross-sectional study. Participants were recruited via the Athena Breast Health Network and via the Young Survival Coalition's social media postings. Descriptive statistics were calculated to understand utilization of and feelings about contraceptive methods before, during, and after breast cancer treatment. RESULTS: Data presented here are from an online survey of 150 breast cancer survivors who completed the survey. Seventy-one percent (n = 105) of respondents reported being sexually active and not pregnant during their primary cancer treatment (surgery, chemotherapy, and/or radiation). Of these, 90% (n = 94) reported using any form of contraceptive, and the most common method was condoms (n = 55, 52%). Respondents reported that safety concerns had the biggest influence on their contraception method choice. Sixty-one percent (n = 92) reported receiving contraceptive counseling by their oncologist either before or after treatment; however, 49% (n = 45) of those did not receive a specific recommendation for a contraceptive method. Of respondents who reported receiving contraceptive counseling from their gynecologist, 44% (n = 35) reported that their gynecologist specifically recommended a copper intrauterine device (IUD). The majority of respondents (n = 76, 52%) wanted their oncologist to discuss contraceptive options with them and preferred to receive this counseling at the time of diagnosis (n = 81, 57%). CONCLUSIONS:Breast cancer survivors in this study remained sexually active across the cancer care continuum and predominantly used condoms as their contraceptive method during treatment. Breast cancerpatients would prefer contraceptive counseling from their oncologist at the time of their cancer diagnosis. IMPLICATION FOR CANCER SURVIVORS: Education efforts in the future should focus on initiatives to improve comprehensive contraceptive counseling at the time of diagnosis by an oncologist.
Entities:
Keywords:
Breast cancer; Contraceptive; Family planning; Reproductive health
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Paniti Sukumvanich; L Doug Case; Kimberly Van Zee; S Eva Singletary; Electra D Paskett; Jeanne A Petrek; Elizabeth Naftalis; Michelle J Naughton Journal: Cancer Date: 2010-07-01 Impact factor: 6.860
Authors: Matteo Lambertini; Claudia Massarotti; Julie Havas; Barbara Pistilli; Anne-Laure Martin; Alexandra Jacquet; Charles Coutant; Florence Coussy; Asma Dhaini Mérimèche; Florence Lerebours; Christine Rousset-Jablonski; Christelle Jouannaud; Olivier Rigal; Marion Fournier; Patrick Soulie; Maria Alice Franzoi; Lucia Del Mastro; Ann H Partridge; Fabrice André; Ines Vaz-Luis; Antonio Di Meglio Journal: JAMA Netw Open Date: 2022-09-01